ClinicalTrials.gg
Active, not recruitingNCT02152631JUNIPERUpdated Feb 6, 2026Results posted

A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer

A Phase 3 interventional study of Abemaciclib and Erlotinib in Non Small Cell Lung Cancer, sponsored by Eli Lilly and Company. Active, not recruiting at 231 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
453
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company — 6 open to participants now, 20 under way, 6 of them phase 3. Carcinoma, Non-Small-Cell Lung · Eli Lilly and Company.

Enrollment
22nd of 139
453 · median 109
Started
2014
with 2 others
Phase 3
25 of 147
2 open now
Primary completion
2017-09
later than 0 of 19 live
Registered
105th of 147
by date

Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 22nd largest by enrollment of the 139 interventional ones that give a count, is one of 3 that started in 2014, is one of 25 in phase 3, reaches primary completion later than 0 of the 19 other live ones, and was the 105th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

6 of the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate how safe and effective the study drug known as abemaciclib is in participants with lung cancer.

03

Conditions studied

  • Non Small Cell Lung Cancer

Keywords

  • Therapy, Platinum, Kras +
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have confirmed diagnosis of stage IV non-small cell lung cancer (NSCLC) according to the American Joint Committee on Cancer Staging Handbook.
  • Determined to have detectable mutations in codons 12 or 13 of the kirsten rat sarcoma (KRAS) oncogene by an assay at the study central laboratory. A KRAS positive mutation result in codons 12 or 13 of the KRAS oncogene from tumor tissue per local laboratory will be permitted in no more than 10% of randomized participants.
  • Have progressed after platinum-based chemotherapy (with or without maintenance therapy) AND have received one additional therapy which may include an or other anti-cancer therapy for advanced and/or disease OR is judged by the physician as ineligible for further standard chemotherapy. Participants who have progressed after platinum-based chemotherapy and an immune checkpoint inhibitor (immunotherapy) e.g. pembrolizumab or nivolumab alone or in combination with other agents are eligible.
  • Have measureable disease as defined by the (RECIST 1.1).
  • Have a performance status (PS) of 0 to 1 on the (ECOG) scale.
  • Have discontinued all previous therapies for cancer (including chemotherapy, radiotherapy, immunotherapy, and investigational therapy) for at least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving study drug.

Exclusion criteria

Exclusion Criteria:

  • Have received treatment with a drug that has not received regulatory approval for any indication within 14 or 21 days of the initial dose of study drug for a nonmyelosuppressive or myelosuppressive agent, respectively.
  • Have a personal history of any of the following conditions: presyncope or syncope of either unexplained or cardiovascular etiology, ventricular arrhythmia (including but not limited to ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest.
  • Have the presence of unstable central nervous system (CNS) . History of or stable CNS metastases is allowed (no longer requiring active therapy such as medications). Participants with a history of CNS metastases must have a brain scan (for example, magnetic resonance imaging [MRI]) within 28 days of randomization to document stability, even if there have been no changes in symptoms.
  • Have previously completed or withdrawn from this study or any other study investigating a cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6) inhibitors, or have received treatment with a prior CDK4 and CDK6 inhibitors.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
453 participants (actual)

Study arms

  • Experimental
    Abemaciclib

    200 milligrams (mg) abemaciclib administered, orally, every 12 hours plus best supportive care (BSC) on Days 1 to 28 (28 day cycles).

    Drug: Abemaciclib

  • Active comparator
    Erlotinib

    150 mg erlotinib administered, orally, every 24 hours plus BSC on Days 1 to 28 (28 day cycles).

    Drug: Erlotinib

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS defined as from randomization date to the date of death due to any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive.

    Time frame: From Randomization Date to Date of Death from Any Cause (Up to 32 Months)

Secondary outcomes

  1. Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])

    ORR was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.

    Time frame: From Randomization Date to Objective Progression (Up to 32 Months)

  2. Progression Free Survival (PFS)

    PFS defined as the from randomization date to the first evidence of disease progression as defined by RECIST v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of first dose, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.

    Time frame: From Randomization Date until Disease Progression or Death from Any Cause (Up to 32 Months)

  3. Change From Baseline in MD Anderson Symptom Inventory-Lung Cancer (MDASI-LC) Score

    The MDASI-LC included 22 items + 3 additional trial-specific items, resulting in 6 collected and reported single-construct scores including core symptoms (13-item), interference (6-item), lung cancer (3-item), and trial-specific single outcomes for headache, diarrhea, and rash. A 2-construct composite core + lung cancer symptom (16-item) score was calculated. Data for all 7 scores were collected by an 11-point numeric rating scale anchored at 0 (not present or does not interfere) and 10 (as bad as you can imagine or interfered completely). The measurement range was 10 (maximum score-minimum score). Mixed Model Repeated Measure (MMRM) regression with covariates for treatment, visit, treatment\*visit, and baseline score predicted between-group Least Squares (LS) mean differences from baseline. Group-level negative change from baseline indicated group improvement.

    Time frame: From Randomization Date through End of Study (Up to 32 Months)

  4. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve During 1 Dosing Interval at Steady State

    PK is determined by the area under the plasma concentration versus time curve during 1 dosing interval at steady state

    Time frame: Day 1 of Cycle 1 through Cycle 3 (28 Day Cycles)

  5. Change From Baseline in European Quality of Life - 5 Dimensions - 5 Level (EQ-5D-5L) Score

    There are 5 response levels on a good-to-bad continuum of 1-5 corresponding to none, slight, moderate, severe, and extreme/unable to. The EuroQol-developed crosswalk method was used to convert the EQ-5D-5L,using United Kingdom (UK) weights, health dimensions(mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) into a single index value; the dimensions are not separately scored. The index is marked missing when ≥1 dimensions are missing. The index scores for the response patterns were anchored on full health to dead with negative values assigned to response patterns/health states considered worse than death. The best pattern is assigned the index value of 1.0; the worst pattern is assigned an index value of -0.594. Between-group differences in regression-predicted change from baseline score were estimated for the index. LS Mean value was controlled for Treatment, visit, Treatment\*Visit and baseline.

    Time frame: From Randomization Date through End of Study (Up to 32 Months)

  6. Resource Utilization: Percentage of Participants Who Are Hospitalized

    Resource utilization is the percentage of participants who was hospitalized.

    Time frame: From Randomization Date through End of Study (Up to 32 Months)

07

Results

Posted Dec 12, 2018

Participant flow

Participant flow — Overall Study
MilestoneAbemaciclibErlotinib
Started270183
Received at least one dose of study drug265175
Off treatment246172
Death due to any cause3020
Progressive disease174137
Completed204157
Not completed6626
Withdrew: Adverse event324
Withdrew: Withdrawal by subject1316
Withdrew: Noncompliance with study drug10
Withdrew: Physician decision12
Withdrew: Lost to follow-up01
Withdrew: On treatment193

Outcome measures

PrimaryOverall Survival (OS)

OS defined as from randomization date to the date of death due to any cause. For each participant who is not known to have died as of the data-inclusion cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive.

Time frame:
From Randomization Date to Date of Death from Any Cause (Up to 32 Months)
Reported as:
Median · months
Overall Survival (OS)
monthsAbemaciclibErlotinib
Overall Survival (OS)7.4 (6.5 to 8.8)7.8 (6.4 to 9.5)
Statistical analysis
  • Abemaciclib vs Erlotinib · Stratified Log-Rank · p = 0.771 · Hazard ratio (hr): 0.968 · 95% CI 0.768 to 1.219Hazard Ratio (HR) was estimated based on Stratified Cox proportional hazard model.
SecondaryPercentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])

ORR was the percentage of participants achieving a best overall response (BOR) of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the longest diameters (LD) of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions.

Time frame:
From Randomization Date to Objective Progression (Up to 32 Months)
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])
percentage of participantsAbemaciclibErlotinib
Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])8.9 (5.5 to 12.3)2.7 (0.4 to 5.1)
Statistical analysis
  • Abemaciclib vs Erlotinib · Cochran-Mantel-Haenszel · p = 0.010
SecondaryProgression Free Survival (PFS)

PFS defined as the from randomization date to the first evidence of disease progression as defined by RECIST v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of first dose, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date.

Time frame:
From Randomization Date until Disease Progression or Death from Any Cause (Up to 32 Months)
Reported as:
Number · months
Progression Free Survival (PFS)
monthsAbemaciclibErlotinib
Progression Free Survival (PFS)3.6 (2.8 to 3.8)1.9 (1.9 to 2.0)
Statistical analysis
  • Abemaciclib vs Erlotinib · Stratified Log-Rank · p = <0.000001 · Hazard ratio (hr): 0.583 · 95% CI 0.470 to 0.723
SecondaryChange From Baseline in MD Anderson Symptom Inventory-Lung Cancer (MDASI-LC) Score

The MDASI-LC included 22 items + 3 additional trial-specific items, resulting in 6 collected and reported single-construct scores including core symptoms (13-item), interference (6-item), lung cancer (3-item), and trial-specific single outcomes for headache, diarrhea, and rash. A 2-construct composite core + lung cancer symptom (16-item) score was calculated. Data for all 7 scores were collected by an 11-point numeric rating scale anchored at 0 (not present or does not interfere) and 10 (as bad as you can imagine or interfered completely). The measurement range was 10 (maximum score-minimum score). Mixed Model Repeated Measure (MMRM) regression with covariates for treatment, visit, treatment\*visit, and baseline score predicted between-group Least Squares (LS) mean differences from baseline. Group-level negative change from baseline indicated group improvement.

Time frame:
From Randomization Date through End of Study (Up to 32 Months)
Reported as:
Least squares mean · units on a scale
Change From Baseline in MD Anderson Symptom Inventory-Lung Cancer (MDASI-LC) Score
units on a scaleAbemaciclibErlotinib
Headache0.20 ± 0.110.27 ± 0.15
Diarrhea1.91 ± 0.171.32 ± 0.23
Rash0.65 ± 0.173.05 ± 0.22
Mean Core Symptom Severity0.49 ± 0.100.73 ± 0.13
Mean Interference0.70 ± 0.140.85 ± 0.18
Mean Lung Cancer Symptom Severity0.16 ± 0.090.23 ± 0.12
Mean Core Plus Lung Cancer Symptom Severity0.44 ± 0.090.65 ± 0.12
Statistical analysis
  • Abemaciclib vs Erlotinib · Mixed Models Analysis · p = 0.698 · Ls mean change difference: -0.07 · 95% CI -0.44 to 0.29Analyzed by Type 3 sums of squares, model covariates included Treatment + Visit + Treatment\*Visit + Baseline.
  • Abemaciclib vs Erlotinib · Mixed Models Analysis · p = 0.038 · Ls mean change difference: 0.59 · 95% CI 0.03 to 1.15Analyzed by Type 3 sums of squares, model covariates included Treatment + Visit + Treatment\*Visit + Baseline.
  • Abemaciclib vs Erlotinib · Mixed Models Analysis · p = <.001 · Ls mean change difference: -2.40 · 95% CI -2.94 to -1.86Analyzed by Type 3 sums of squares, model covariates included Treatment + Visit + Treatment\*Visit + Baseline.
  • Abemaciclib vs Erlotinib · Mixed Models Analysis · p = 0.142 · Ls mean change difference: -0.24 · 95% CI -0.56 to 0.08Analyzed by Type 3 sums of squares, model covariates included Treatment + Visit + Treatment\*Visit + Baseline.
  • Abemaciclib vs Erlotinib · Mixed Models Analysis · p = 0.514 · Ls mean change difference: -0.15 · 95% CI -0.59 to 0.30Analyzed by Type 3 sums of square, model covariates included Treatment + Visit + Treatment\*Visit + Baseline.
  • Abemaciclib vs Erlotinib · Mixed Models Analysis · p = 0.646 · Ls mean change difference: -0.07 · 95% CI -0.37 to 0.23Analyzed by Type 3 sums of squares, model covariates included Treatment + Visit + Treatment\*Visit + Baseline.
  • Abemaciclib vs Erlotinib · Mixed Models Analysis · p = 0.188 · Ls mean change difference: -0.20 · 95% CI -0.51 to 0.10Analyzed by Type 3 sums of squares, model covariates included Treatment + Visit + Treatment\*Visit + Baseline.
SecondaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve During 1 Dosing Interval at Steady State

PK is determined by the area under the plasma concentration versus time curve during 1 dosing interval at steady state

Time frame:
Day 1 of Cycle 1 through Cycle 3 (28 Day Cycles)
Reported as:
Geometric mean · Hour*nanogram/milliliter (h*ng/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve During 1 Dosing Interval at Steady State
Hour*nanogram/milliliter (h*ng/mL)Abemaciclib
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve During 1 Dosing Interval at Steady State3350 ± 52
SecondaryChange From Baseline in European Quality of Life - 5 Dimensions - 5 Level (EQ-5D-5L) Score

There are 5 response levels on a good-to-bad continuum of 1-5 corresponding to none, slight, moderate, severe, and extreme/unable to. The EuroQol-developed crosswalk method was used to convert the EQ-5D-5L,using United Kingdom (UK) weights, health dimensions(mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) into a single index value; the dimensions are not separately scored. The index is marked missing when ≥1 dimensions are missing. The index scores for the response patterns were anchored on full health to dead with negative values assigned to response patterns/health states considered worse than death. The best pattern is assigned the index value of 1.0; the worst pattern is assigned an index value of -0.594. Between-group differences in regression-predicted change from baseline score were estimated for the index. LS Mean value was controlled for Treatment, visit, Treatment\*Visit and baseline.

Time frame:
From Randomization Date through End of Study (Up to 32 Months)
Reported as:
Least squares mean · units on a scale
Change From Baseline in European Quality of Life - 5 Dimensions - 5 Level (EQ-5D-5L) Score
units on a scaleAbemaciclibErlotinib
Change From Baseline in European Quality of Life - 5 Dimensions - 5 Level (EQ-5D-5L) Score-0.08 ± 0.01-0.08 ± 0.02
Statistical analysis
  • Abemaciclib vs Erlotinib · Mixed Models Analysis · p = 0.951 · Ls mean change difference: -0.00 · 95% CI -0.05 to 0.05Analyzed By Type 3 sums of squares, Change from Baseline = Treatment + Visit + Treatment\*Visit + Baseline.
SecondaryResource Utilization: Percentage of Participants Who Are Hospitalized

Resource utilization is the percentage of participants who was hospitalized.

Time frame:
From Randomization Date through End of Study (Up to 32 Months)
Reported as:
Number · percentage of participants
Resource Utilization: Percentage of Participants Who Are Hospitalized
percentage of participantsAbemaciclibErlotinib
Resource Utilization: Percentage of Participants Who Are Hospitalized40.422.9

Adverse events

Collected over From Baseline to End of Study (Up to 47 Months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abemaciclib186/265 (70.2%)112/265 (42.3%)247/265 (93.2%)
Erlotinib123/175 (70.3%)43/175 (24.6%)161/175 (92%)
Most frequent serious events
Showing 10 of 126
Most frequent serious events
EventAbemaciclibErlotinib
PneumoniaInfections and infestations13/2656/175
DyspnoeaRespiratory, thoracic and mediastinal disorders8/2657/175
DiarrhoeaGastrointestinal disorders10/2650/175
DehydrationMetabolism and nutrition disorders10/2651/175
Acute kidney injuryRenal and urinary disorders10/2651/175
NauseaGastrointestinal disorders7/2650/175
VomitingGastrointestinal disorders5/2652/175
AnaemiaBlood and lymphatic system disorders3/2653/175
PneumonitisRespiratory, thoracic and mediastinal disorders3/2653/175
Pulmonary embolismRespiratory, thoracic and mediastinal disorders4/2651/175
Most frequent other events
Showing 10 of 35
Most frequent other events
EventAbemaciclibErlotinib
DiarrhoeaGastrointestinal disorders169/26569/175
Decreased appetiteMetabolism and nutrition disorders95/26542/175
NauseaGastrointestinal disorders94/26530/175
AnaemiaBlood and lymphatic system disorders87/26523/175
FatigueGeneral disorders73/26529/175
Dermatitis acneiformSkin and subcutaneous tissue disorders1/26546/175
RashSkin and subcutaneous tissue disorders11/26542/175
VomitingGastrointestinal disorders61/26515/175
DyspnoeaRespiratory, thoracic and mediastinal disorders53/26522/175
Blood creatinine increasedInvestigations45/2652/175

Baseline characteristics

Age, Continuous
Age, Continuous(years)AbemaciclibErlotinibTotal
Mean62.3 ± 8.962.9 ± 8.462.5 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)AbemaciclibErlotinibTotal
Female10774181
Male163109272
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)AbemaciclibErlotinibTotal
Hispanic or Latino131225
Not Hispanic or Latino197132329
Unknown or Not Reported603999
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AbemaciclibErlotinibTotal
American Indian or Alaska Native011
Asian564197
Native Hawaiian or Other Pacific Islander000
Black or African American123
White165106271
More than one race314
Unknown or Not Reported453277
Region of Enrollment
Region of Enrollment(Participants)AbemaciclibErlotinibTotal
Argentina123
Romania7714
United States443074
Japan221739
Ukraine6511
Russia8412
Spain261339
Greece167
Canada448
Austria022
South Korea131326
Turkey21829
China7411
Taiwan12719
Brazil7512
Poland628
Italy51217
Israel516
France353267
Germany301444
08

Study locations

231 sites
  • Highlands Oncology Group
    Fayetteville, Arkansas 72703, United States
  • St. Bernards Medical Center
    Jonesboro, Arkansas 72401, United States
  • City of Hope National Medical Center
    Duarte, California 91010, United States
  • University of California - San Diego
    La Jolla, California 92037, United States
  • Loma Linda University School of Medicine
    Loma Linda, California 92350, United States
  • CBCC Global Research, Inc.
    Los Angeles, California 90024, United States
  • Central Coast Medical Oncology Corporation
    Los Angeles, California 90024, United States
  • Fort Wayne Oncology & Hematology
    Los Angeles, California 90024, United States
  • SMO TRIO -Translational Research
    Los Angeles, California 90024, United States
  • St. Joseph Heritage Medical Group
    Los Angeles, California 90024, United States
  • UCLA Department of Medicine-Hematology/Oncology
    Los Angeles, California 90024, United States
  • Cancer Care Associates Medical Group
    Los Angeles, California 90095, United States
  • Dignity Health Care Institute
    Sacramento, California 95816, United States
  • Alegent Immanuel Cancer Center
    Englewood, Colorado 80112, United States
  • Jewish Hospital
    Englewood, Colorado 80112, United States
  • Oncology Hematology West
    Englewood, Colorado 80112, United States
  • SMO Catholic Health Initiatives
    Englewood, Colorado 80112, United States
  • St Joseph Cancer Center
    Englewood, Colorado 80112, United States
  • St. Francis Medical Center
    Englewood, Colorado 80112, United States
  • Medical Oncology Hematology Consultants
    Newark, Delaware 19713, United States
  • Boca Raton Regional Hospital
    Boca Raton, Florida 33486, United States
  • Halifax Medical Center
    Daytona Beach, Florida 32114, United States
  • Memorial Cancer Institute
    Pembroke Pines, Florida 33028, United States
  • H Lee Moffitt Cancer Center
    Tampa, Florida 33612-9497, United States
  • University Cancer & Blood Center, LLC
    Athens, Georgia 30607, United States
  • Ingalls Memorial Hospital
    Harvey, Illinois 60426, United States
  • Indiana University School of Medicine
    Indianapolis, Indiana 46202, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Cancer Center of Kansas, P.A.
    Wichita, Kansas 67214, United States
  • Central Baptist Hospital
    Lexington, Kentucky 40503, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Walter Reed National Military Medical Center
    Bethesda, Maryland 20889, United States
  • Metro-West and Greater Boston CNS Research
    Framingham, Massachusetts 01701, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Mercy Medical Research Institute
    Springfield, Missouri 65807, United States
  • Billings Clinic Research Center
    Billings, Montana 59101, United States
  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Broome Oncology
    Johnson City, New York 13790, United States
  • Weill Cornell Medical College
    New York, New York 10065, United States
  • Oncology Hematology Care Inc
    Cincinnati, Ohio 45242, United States
  • Oklahoma Cancer Specialists & Research Institute, LLC
    Tulsa, Oklahoma 74146, United States
  • Providence Cancer Center Oncology Hematology Care
    Portland, Oregon 97213, United States
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15213, United States
  • Roper St. Francis Healthcare
    Charleston, South Carolina 29401, United States
  • Chattanooga Oncology Hematology Associates
    Chattanooga, Tennessee 37404, United States
  • Chattanooga Oncology Hematology Associates
    Nashville, Tennessee 37203, United States
  • Tennessee Oncology PLLC
    Nashville, Tennessee 37203, United States
  • Mary Crowley Cancer Research Center
    Dallas, Texas 75230, United States
  • Utah Cancer Specialists
    Salt Lake City, Utah 84106, United States
  • University of Vermont Medical Center
    Burlington, Vermont 05401, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • Kadlec Clinical Hematology & Oncology
    Kennewick, Washington 99336, United States
  • Swedish Medical Center
    Seattle, Washington 98104, United States
  • Cancer Care Northwest
    Valley, Washington 99216, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Berazategui, B1884BBF, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ciudad Autonoma Buenos Aires, 1025, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ciudad Autonoma Buenos Aires, 1093, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ciudad Autonoma Buenos Aires, C1181AAX, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rosario, 2000, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Rosario, S2000DSV, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Viedma, 8500, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Graz, 8036, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Linz, 4020, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Linz, 4021, Austria
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Salzburg, 5020, Austria
  • Associação Hospital de Caridade Ijuí
    Ijuí, 98700 000, Brazil
  • Hospital Bruno Born
    Lajeados, 95900-000, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Porto Alegre, 90610-970, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rio de Janeiro, 20231-050, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Salvador, 41253-190, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sao Jose Rio Preto, 15090-000, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    São Paulo, 01246000, Brazil
  • Fundação Antonio Prudente - Hospital do Câncer A.C Camargo
    São Paulo, 01509-010, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Calgary, T2N 4N2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Edmonton, T6G 1Z2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Montreal, H2L 4M1, Canada
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Toronto, M4N 3M5, Canada
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Vancouver, V5Z 4E6, Canada
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Winnipeg, R3A 1M3, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Beijing, 100021, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Beijing, 100071, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Beijing, 100730, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Changchun, 130012, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Changzhou, 213000, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chengdu, 610041, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Haikou, 570311, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hangzhou, 310022, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hefei, 230001, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nanning, 530021, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shanghai, 200030, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shenyang, 100042, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bron, 69677, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Dijon, 21034, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Grenoble, 38043, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lille, 59037, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Marseille, 13015, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Poitiers, 86021, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rennes, 35033, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician
    Saint-Brieuc, 22027, France
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saint-Priest-en-Jarez, 42270, France

Showing the first 100 of 231 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Goldman JW, Mazieres J, Barlesi F, Dragnev KH, Koczywas M, Goskel T, Cortot AB, Girard N, Wesseler C, Bischoff H, Nadal E, Park K, Lu S, Taus A, Cobo M, Estrem ST, Wijayawardana SR, Turner K, Oakley GJ 3rd, Hurt KC, Chiang AY, Hossain AM, John WJ, Paz-Ares L. A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER. Front Oncol. 2020 Oct 26;10:578756. doi: 10.3389/fonc.2020.578756. eCollection 2020. PubMed 33194700 ↗
  • Goldman JW, Shi P, Reck M, Paz-Ares L, Koustenis A, Hurt KC. Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non-Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy. Clin Lung Cancer. 2016 Jan;17(1):80-4. doi: 10.1016/j.cllc.2015.08.003. Epub 2015 Aug 18. PubMed 26432508 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2014 to primary completion in Sep 2017, 35 months.

Results were first posted in Dec 2018, 1 year 2 months after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 35 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2014
First posted
Jun 2, 2014
StartActual
Oct 3, 2014
Primary completionActual
Sep 15, 2017
CompletionEst.
Dec 2026
Results first posted
Dec 12, 2018
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02152631
Responsible party
Sponsor
First posted
Jun 2, 2014
Start date
Oct 3, 2014
Primary completion
Sep 15, 2017
Completion
Dec 2026 (estimated)
Results posted
Dec 12, 2018
Last update
Feb 6, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abemaciclib

Start the discussion